Here is the kill shot from the analyst Irina Rivkind. Nothing but mumbled #$%$ in response.
Irina Rivkind - Cantor Fitzgerald & Co., Research Division
And the second question is on RELISTOR. Just looking at some other companies developing products in the space, mu-opioid antagonists. They've had to do one-year long, open-label safety trials at about 1,200 to 1,400 patients. So I mean, why would the FDA let you guys off the hook and not force you to do the same thing?
Basically the answer, to the effect, was that SLXP didn't have the same number of patients enrolled because that was not the requirement from the FDA when they started the trial. Other companies may have done better homework but SLXP can't comment on that. This is almost like a D student doesn't know how A student got the better grade.